Access Considerations for People Aging with HIV: IRA Negotiations and BIKTARVY®
August 28, 2026The Centers for Medicare & Medicaid Services (CMS) recently selected 15 Medicare-covered drugs for the third cycle of Medicare drug price negotiation, known as IPAY 2028, under the Inflation Reduction Act (IRA).
BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide), a widely used single-tablet HIV treatment regimen, is one of the selected drugs.
This fact sheet provides information and considerations on these negotiations.
Joint Statement and Public Comments on the Proposed Changes to Connecticut’s Medicaid Protected Drug Classes
April 29, 2026ADAP Advocacy and HealthHIV issued the following joint statement in response to the proposed changes to services for People Living with HIV/AIDS (PLWHA) under Medicaid as set forth in the Connecticut Governor’s Health and Human Services budget recommendations.
CMS Town Hall Meeting on Biktarvy Price Negotiations: Comments by Kevin Herwig
April 23, 2026Comments provided by Kevin Herwig, HIV+Hepatitis Policy Institute, during the Centers for Medicare and Medicaid Services Town Hall Meeting on Biktarvy Price Negotiations, April 22, 2026.
